The expanding landscape of GLP-1 medicines
Nat Med. 2026 Jan 2. doi: 10.1038/s41591-025-04124-5. Online ahead of print.ABSTRACTGlucagon-like peptide-1 medicines are being prescribed to growing numbers of patients worldwide, for type 2 diabetes, obesity and associated comorbidities, including cardiovascular disease, peripheral artery disease

